Newsletter
The monthly digest
A summary of every article we published, once a month. Subscribe via the form in the footer.
October 2026
AlpinaBioTech Digest - October 2026
October's articles converge on a single structural shift in bioanalysis: as regulatory agencies in the US, EU, and Canada reduce or eliminate comparative efficacy and pharmacokinetic bridging requirements for biosimilar approval, the evidentiary burden falls almost entirely on PK and anti-drug antibody assays. Two articles this month examine this directly, one working through the three converging guidance documents from 2025 and 2026 and what they demand at the platform design level, and one focused specifically on FDA's March 2026 draft guidance and its implications for ADA assay drug tolerance, sensitivity, and neutralizing antibody assessment before clinical samples are ever collected.
6 articles
September 2026
AlpinaBioTech Digest - September 2026
September's articles cover a wide methodological range, but a common thread runs through several of them: the analyte you intend to measure is not always the analyte circulating in the sample. That problem appears in different forms in ADC bioanalysis, where deconjugation and DAR shift alter the species present after dosing; in multi-biomarker Alzheimer's panels, where femtomolar sensitivity requirements and cross-reactivity between tau isoforms make harmonization across platforms difficult; and in denosumab ADA programs, where soluble RANKL interference in the assay determines whether a reported incidence figure is interpretable at all.
6 articles
August 2026
AlpinaBioTech Digest - August 2026
This month's six articles center heavily on biosimilar monitoring, where the measurement questions are becoming more pressing as real-world switching data accumulate without systematic therapeutic drug monitoring or anti-drug antibody testing built in. Two pieces examine anti-TNF and anti-CD20 biosimilars directly: one reviews what a post-switch trough level drop in pediatric adalimumab cohorts means for laboratory protocols, and another draws on the BRAVO multicenter cohort to argue that equivalent six-month clinical outcomes in rituximab-treated AAV patients reinforce, rather than reduce, the rationale for structured pharmacokinetic and immunogenicity monitoring. All assays and products described are for Research Use Only.
6 articles
July 2026
AlpinaBioTech Digest - July 2026
This month's articles cover three areas with direct implications for laboratories running immunogenicity and therapeutic drug monitoring assays. All content is published for Research Use Only.
3 articles
June 2026
AlpinaBioTech Digest - June 2026
This month's ten articles concentrate on a shift that is already affecting bioanalytical workflows: the redistribution of regulatory evidentiary weight onto PK and anti-drug antibody assays in biosimilar development. EMA's March 2026 reflection paper removes the comparative efficacy study requirement for well-characterised biologics, a change illustrated in practice by the CHMP's June 2026 positive opinion for Denosumab Ascend. A companion piece examines how a May 2026 scoping review in JAMA Health Forum and the FDA's March 2026 Revision 4 draft guidance together expose persistent inconsistencies in immunogenicity requirements across 19 countries, with direct consequences for ADA assay validation scope, cut-point frameworks, and sampling schedules in global programs. All assays and data discussed in these articles are for Research Use Only.
10 articles